# Osteoblast-derived vesicles induce a switch from bone-formation to bone-resorption in vivo

**Authors:** Maki Uenaka, Erika Yamashita, Junichi Kikuta, Akito Morimoto, Tomoka Ao, Hiroki Mizuno, Masayuki Furuya, Tetsuo Hasegawa, Hiroyuki Tsukazaki, Takao Sudo, Keizo Nishikawa, Daisuke Okuzaki, Daisuke Motooka, Nobuyoshi Kosaka, Fuminori Sugihara, Thomas Boettger, Thomas Braun, Takahiro Ochiya, Masaru Ishii

PMC · DOI: 10.1038/s41467-022-28673-2 · Nature Communications · 2022-02-24

## TL;DR

Mature osteoblasts release vesicles that shift bone metabolism from building to breaking down by inhibiting bone formation and promoting osteoclast activity.

## Contribution

The study identifies small osteoblast vesicles (SOVs) as key mediators of the switch from bone formation to resorption via miR-143.

## Key findings

- SOVs suppress osteoblast differentiation and enhance osteoclastogenesis by increasing RANKL expression.
- miR-143 in SOVs inhibits Runx2 by targeting Cbfb mRNA, a key regulator of osteoblast development.
- SOVs act as extracellular vesicles mediating cell-to-cell communication during bone remodeling.

## Abstract

Bone metabolism is regulated by the cooperative activity between bone-forming osteoblasts and bone-resorbing osteoclasts. However, the mechanisms mediating the switch between the osteoblastic and osteoclastic phases have not been fully elucidated. Here, we identify a specific subset of mature osteoblast-derived extracellular vesicles that inhibit bone formation and enhance osteoclastogenesis. Intravital imaging reveals that mature osteoblasts secrete and capture extracellular vesicles, referred to as small osteoblast vesicles (SOVs). Co-culture experiments demonstrate that SOVs suppress osteoblast differentiation and enhance the expression of receptor activator of NF-κB ligand, thereby inducing osteoclast differentiation. We also elucidate that the SOV-enriched microRNA miR-143 inhibits Runt-related transcription factor 2, a master regulator of osteoblastogenesis, by targeting the mRNA expression of its dimerization partner, core-binding factor β. In summary, we identify SOVs as a mode of cell-to-cell communication, controlling the dynamic transition from bone-forming to bone-resorbing phases in vivo.

Bone remodeling involves a switch between bone formation and resorption, but the mechanisms is unclear. Here, the authors show that intercellular communication via extracellular vesicles secreted by mature osteoblasts is a key factor for the switching, via a microRNA-mediated mechanism.

## Linked entities

- **Genes:** RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860], CBFB (core-binding factor subunit beta) [NCBI Gene 865]
- **Proteins:** TNFSF11 (TNF superfamily member 11)

## Full-text entities

- **Genes:** Igf1 (insulin-like growth factor 1) [NCBI Gene 16000] {aka C730016P09Rik, Igf-1, Igf-I}, Mir143 (microRNA 143) [NCBI Gene 387161] {aka Mirn143, mir-143, mmu-mir-143}, Efnb2 (ephrin B2) [NCBI Gene 13642] {aka ELF-2, Epl5, Eplg5, Htk-L, LERK-5, Lerk5}, Sp7 (Sp7 transcription factor 7) [NCBI Gene 170574] {aka 6430578P22Rik, C22, Osx}, Ctsk (cathepsin K) [NCBI Gene 13038] {aka MMS10-Q, Ms10q, catK}, AOPEP (aminopeptidase O (putative)) [NCBI Gene 84909] {aka AP-O, APO, C90RF3, C9orf3, DYT31, ONPEP}, Cd63 (CD63 antigen) [NCBI Gene 12512] {aka ME491, Tspan30}, Pth (parathyroid hormone) [NCBI Gene 19226] {aka Pthp}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, SP7 (Sp7 transcription factor) [NCBI Gene 121340] {aka OI11, OI12, OSX, osterix}, Mir148a (microRNA 148a) [NCBI Gene 387166] {aka Mirn148, Mirn148a, mir-148a}, Sema4d (sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D) [NCBI Gene 20354] {aka CD100, Semacl2, Semaj, Semcl2, coll-4}, Mir21a (microRNA 21a) [NCBI Gene 387140] {aka Mir21, Mirn21, mmu-mir-21, mmu-mir-21a}, Rnase1 (ribonuclease, RNase A family, 1 (pancreatic)) [NCBI Gene 19752] {aka Rib-1, Rib1}, Acp5 (acid phosphatase 5, tartrate resistant) [NCBI Gene 11433] {aka TRACP, TRAP}, Alpl (alkaline phosphatase, liver/bone/kidney) [NCBI Gene 11647] {aka ALP, APTNAP, Akp-2, Akp2, TNAP, TNSALP}, Bglap (bone gamma carboxyglutamate protein) [NCBI Gene 12096] {aka BGP, Bglap1, OC, OG1, mOC-A}, Cfp (complement factor properdin) [NCBI Gene 18636] {aka BCFG, Pfc}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, MIR143 (microRNA 143) [NCBI Gene 406935] {aka MIRN143, mir-143}, Mir145a (microRNA 145a) [NCBI Gene 387163] {aka Mir145, Mirn145, mir-145a, mmu-mir-145, mmu-mir-145a}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Mir215 (microRNA 215) [NCBI Gene 387211] {aka Mirn215, mir-215, mmu-mir-215}, Hdac3 (histone deacetylase 3) [NCBI Gene 15183], Col1a1 (collagen, type I, alpha 1) [NCBI Gene 12842] {aka Col1a-1, Cola-1, Cola1, Mov-13, Mov13}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Runx2 (runt related transcription factor 2) [NCBI Gene 12393] {aka AML3, CBF-alpha-1, Cbf, Cbfa-1, Cbfa1, LS3}, Csf1 (colony stimulating factor 1 (macrophage)) [NCBI Gene 12977] {aka BAP025, Csfm, MCSF, Mhdabap25, PG-M-CSF, op}, CD63 (CD63 molecule) [NCBI Gene 967] {aka AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40}, Cbfb (core binding factor beta) [NCBI Gene 12400] {aka PEA2, PEBP2b, Pebp2, Pebpb2}, Cthrc1 (collagen triple helix repeat containing 1) [NCBI Gene 68588] {aka 1110014B07Rik}, Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, CBFB (core-binding factor subunit beta) [NCBI Gene 865] {aka CLCD2, PEBP2B}, Atp6v0d2 (ATPase, H+ transporting, lysosomal V0 subunit D2) [NCBI Gene 242341] {aka 1620401A02Rik, V-ATPase}, Hdac7 (histone deacetylase 7) [NCBI Gene 56233] {aka 5830434K02Rik, HD7, HD7a, Hdac7a, mFLJ00062}, Tnfrsf11b (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)) [NCBI Gene 18383] {aka OCIF, Opg, TR1}
- **Diseases:** bone resorption (MESH:D001862), SOVs (MESH:C567751), resorption (MESH:D014091), osteoporosis (MESH:D010024), LEV (OMIM:113900), calvarial defects (MESH:C537963), Bone defects (MESH:D001847), Defect (MESH:D000013)
- **Chemicals:** ascorbic acid (MESH:D001205), Lipofectamine (MESH:C086724), polybrene (MESH:D006583), ethanol (MESH:D000431), CO2 (MESH:D002245), streptomycin (MESH:D013307), lipid (MESH:D008055), osmium tetroxide (MESH:D009993), glycolmethacrylate (MESH:C005044), 7-AAD (MESH:C025942), sodium acetate (MESH:D019346), 1 alpha,25-dihydroxyvitamin D3 (MESH:D002117), alpha-MEM (MESH:C420642), methylmethacrylate (MESH:D020366), creatinine (MESH:D003404), penicillin (MESH:D010406), toluidine blue (MESH:D014048), water (MESH:D014867), PBS (MESH:D007854), epoxy resin (MESH:D004853), beta-glycerophosphate (MESH:C031463), saline (MESH:D012965), Naphthol AS-MX phosphate (MESH:C084845), neomycin (MESH:D009355), teriparatide (MESH:D019379), Col2.3 (-), isoflurane (MESH:D007530), sphingosine-1-phosphate (MESH:C060506), propylene oxide (MESH:C009068), doxycycline (MESH:D004318), Fast blue BB salt (MESH:C016446), EDTA (MESH:D004492), Calcein (MESH:C007740), sodium tartrate (MESH:C029768), Fast Green (MESH:C035906), copper (MESH:D003300), Alexa Fluor 555 (MESH:C000608607), Alizarin Red S (MESH:C004468), paraformaldehyde (MESH:C003043),  (MESH:D053245)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), S2d — Mus musculus (Mouse), Hybridoma (CVCL_C5HT), Nikon A1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), mOB — Homo sapiens (Human), Transformed cell line (CVCL_2302), MC3T3-E1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0409), Col2.3 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2475)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8873258/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8873258/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC8873258/full.md

---
Source: https://tomesphere.com/paper/PMC8873258